Preclinical Imaging (In-VIVO)

Preclinical Imaging (In-VIVO)

Global Preclinical Imaging (In-VIVO) Market to Reach US$1.4 Billion by 2030

The global market for Preclinical Imaging (In-VIVO) estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Preclinical Imaging Modalities, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$900.1 Million by the end of the analysis period. Growth in the Preclinical Imaging Reagents segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$278.7 Million While China is Forecast to Grow at 4.6% CAGR

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$278.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$225.2 Million by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Preclinical Imaging (In-VIVO) Market - Key Trends and Drivers Summarized>Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer`s disease and Parkinson`s disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

Select Competitors (Total 38 Featured) -

• Aspect Imaging Ltd.
• Bruker Corp.
• Idex Health & Science LLC
• Mauna Kea Technologies
• Mediso Ltd.
• Milabs B.V.
• Miltenyi Biotech GmbH
• MR Solutions
• New England Biolabs
• PerkinElmer, Inc.
• Siemens A.G.
• Trifoil Imaging, Inc.
• FujiFilm VisualSonics, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.